Glucocorticoid and immunoglobulin to treat viral fulminant myocarditis
Key result
The application of glucocorticoids and IVIG in the treatment of fulminant myocarditis is considered reasonable, though caution is advised for COVID-19 patients with myocardial damage.
Population
Patients with viral fulminant myocarditis, specifically coronavirus-induced
Design
Editorial
Authors
Discussion
Loading...
Member takes
Key expert perspectives
Captured external expert commentary on this paper, strongest first. Original sources are linked where available.
“We believe that the application of a glucocorticoid and IVIG in the treatment of fulminant myocarditis is reasonable and worthy of further exploration. As the mechanism of coronavirus myocardial damage is still not yet confirmed and may be different from this case, we should be cautious in the use of a glucocorticoid and IVIG for COVID-19 patients with myocardial damage.”
Implication
Early application of glucocorticoids and IVIG may be reasonable for treating viral fulminant myocarditis, though caution is advised for COVID-19 patients until mechanisms are better understood.
Key Points
- To discuss the therapeutic rationale, safety, and clinical considerations of combining glucocorticoids and intravenous immunoglobulin in viral fulminant myocarditis.
- Expert commentary synthesizing clinical observations from a coronavirus fulminant myocarditis case and broader myocarditis literature.
- Review of pharmacological mechanisms of glucocorticoids and intravenous immunoglobulin (IVIG), alongside European Society of Cardiology recommendations.
- Glucocorticoids suppress inflammatory edema and improve left ventricular function in viral myocarditis without increasing viral replication.
- Early administration of adequate-dose IVIG combined with glucocorticoids is observed to shorten the clinical disease course and reduce the incidence of multi-organ failure.
Structured PICO
P
Population
A commentary discussing a single case of coronavirus fulminant myocarditis treated with glucocorticoids and intravenous immunoglobulin.
I
Intervention
Glucocorticoid and intravenous immunoglobulin (IVIG)
Early application of glucocorticoids and IVIG may be reasonable for treating viral fulminant myocarditis, though caution is advised for COVID-19 patients until mechanisms are better understood.
Limitations
- The mechanism of coronavirus myocardial damage is still not yet confirmed and may be different from this case.
- Lack of high-quality clinical research evidence for timing, dosage, and duration of glucocorticoid usage
- Mechanism of coronavirus myocardial damage is still not yet confirmed
Cite This Study
Wei et al. (2020) conducted an editorial in coronavirus fulminant myocarditis (n=1). Glucocorticoid and intravenous immunoglobulin (IVIG) was evaluated. The application of glucocorticoids and IVIG in the treatment of fulminant myocarditis is considered reasonable, though caution is advised for COVID-19 patients with myocardial damage.